Mostrando 4 resultados de: 4
Publisher
Cancer Research(1)
Journal of Biological Chemistry(1)
Journal of Enzyme Inhibition and Medicinal Chemistry(1)
PLoS ONE(1)
Área temáticas
Enfermedades(3)
Fisiología y materias afines(2)
Farmacología y terapéutica(1)
Fisiología humana(1)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(4)
ODS 9: Industria, innovación e infraestructura(4)
Origen
scopus(4)
Down-regulation of hypoxia-inducible factor-2 in PC12 cells by nerve growth factor stimulation
ArticleAbstract: Cellular responses to low oxygen tension are mediated, at least in part, by the activation of the hyPalabras claves:Autores:Álvarez-Tejado M., Castellanos M.C., Manuel Ortiz de Landázuri, Naranjo-Suárez S., Peso L.D., Vara A.Fuentes:scopusHypoxia inducible factor 1-alpha (hif-1 alpha) is induced during reperfusion after renal ischemia and is critical for proximal tubule cell survival
ArticleAbstract: Acute tubular necrosis (ATN) caused by ischemia/reperfusion (I/R) during renal transplantation delayPalabras claves:Autores:Aguado-Fraile E., Alegre L., Blanco-Sánchez I., Conde E., Garcia-Bermejo M.L., Jiménez C., Liaño F., López-Cabrera M., Manuel Ortiz de Landázuri, Ordóñez A., Peso L.D., Ponte B., Ramos E., Sáenz-Morales D., Sáiz A., Sanchez-Tomero J.A., Selgas R.Fuentes:scopusSpecific Oncolytic Effect of a New Hypoxia-Inducible Factor-Dependent Replicative Adenovirus on von Hippel-Lindau-Defective Renal Cell Carcinomas
ArticleAbstract: Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene are responsible for a hereditary cancPalabras claves:Autores:Aragonés J., Castellanos M.C., Cuevas Y., Esteban M.A., Hernández-Alcoceba R., Manuel Ortiz de Landázuri, Martin-Puig S., Naranjo-Suárez S., Peso L.D.Fuentes:scopusTargeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: The METOXIA consortium
ReviewAbstract: The hypoxic areas of solid cancers represent a negative prognostic factor irrespective of which treaPalabras claves:Bioreductive compounds, cancer-treatment resistance, carbonic anhydrase inhibitors, dual-activity compounds, non-invasive oxygen detection, targets for new treatmentAutores:Ahmed A., Alsner J., Ashcroft M., Buffa F.M., Busk M., Calzada M.J., Cao Y., Chiche J., Cojocari D., Dubois L., Ebbesen P., Flamm H., Flatmark K., Gieling R.G., Görlach A., Haider S., Harris A.L., Jobst G., Kieninger J., Koritzinsky M., Kunkler I.H., Lambin P., Langdon S.P., Lyng H., Manuel Ortiz de Landázuri, Marchiq I., Mazure N., Meehan J., Moser I., Mujcic H., Overgaard J., Parks S., Pastorekova S., Peso L.D., Pettersen E.O., Pouyssegur J., Ree A.H., Rouschop K.M., Scozzafava A., Singleton D.C., Supuran C.T., Toustrup K., Urban G., Ward C., Weltin A., Williams K.J., Wouters B.G.Fuentes:scopus